seminar: advertising obligations & liabilities · what is happening? • after decades...
TRANSCRIPT
Seminar: Advertising Obligations & Liabilities16 April 2020
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
INTRODUCTIONS
Deon Schoombie, CEO of CHP Australia
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
AGENDA
1. Setting the context (10 minutes)-Steve Scarff, Regulatory & Legal Director of CHP Australia
2. Understanding advertising obligations & liabilities (30 minutes)
-Gillian Mitchell, First Assistant Secretary Regulatory Practice and Support Division, Department of Health
-Nicole McLay, Assistant Secretary Regulatory Compliance from the Department of Health
3. Industry Perspective & future situation (30 minutes)-Steve Scarff, Regulatory & Legal Director of CHP Australia
4. Questions (45 minutes)
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
SETTING THE CONTEXT
Steve Scarff, Regulatory & Legal Director of CHP Australia
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
SETTING THE CONTEXT
There has been a great deal of recent change
1. Increased sanctions and penalties in place
2. New TGAC (advertising code) in place
3. New complaints systems in place
4. ‘Grace period’ finished
5. Safeguard of mandatory pre-approvals ends 30 June 2020
6. We will be offering an Advertising Advisory Service- AdCheck
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
How can advertisers and those who “cause the advertising”
understand and meet their advertising obligations?
Obligations & Liabilities: Now and Post- 1 July
6
OBLIGATIONS & LIABILITIES NOW AND POST- 1 JULY
Gillian Mitchell,
First Assistant Secretary Regulatory Practice and
Support Division, Department of Health
Nicole McLay,
Assistant Secretary Regulatory Compliance from the
Department of Health
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
The Advertising Reforms and Your Obligations
Your Advertising Obligations & Liabilities Virtual Seminar
Ms Gillian Mitchell / Ms Nicole McLay
Regulatory Compliance
Regulatory Practice and Support Division
Therapeutic Goods Administration
16 April 2020
Therapeutic goods advertising reforms
➢ Mandatory pre-approval of certain ads ends 1 July 2020
➢ Stronger compliance framework – enhanced sanctions and penalties in the Act
➢ Amended Therapeutic Goods Advertising Code – more prescriptive
➢ Single body for compliance and complaints handling
➢ Education program, Advertising Hub
➢ Therapeutic Goods Advertising Consultative Committee (TGACC)
9
Independent review of the reforms to the therapeutic goods advertising framework
• The review of the impact of the advertising reforms has commenced
➢Led by Ms Rosemary Sinclair, AM
➢Workshops have been conducted with members of the TGACC
• Consultation
➢Feedback to be provided via TGACC members by 22 April 2020
10
Advertising responsibilities
be aware of advertising requirements under the Act and Code
keep abreast of information in the Advertising Hub and Compliance and
Enforcement Hub on the TGA website
use the enquiry option on the TGA website to clarify the requirements, or seek
the advice of a regulatory affairs consultant or ad assessment service
obligations are the same whether you advertise or cause the advertising*
report non-compliance to the TGA
* A limited publisher’s defence available where they can show they took reasonable steps to
determine the ad was compliant with the Code
– applies to a broadcaster, datacaster, the SBS, publisher of print newspaper or magazine11
Industry Perspective & and Future Situation
12
OUTLINE
• What is happening?
• Why is the Government abolishing mandatory pre-approvals?
• What else has changed?
• What will take the place of mandatory pre-approvals?
• How will the new service work?
• What does it mean to “advertise”?
• What does it mean to “cause” advertising?
• Publisher exceptions?
• Why does CHP Australia support preapprovals (now) and compliance reviews (in the future)?
• Why would you want to use the new AdCheck service?
• Summary
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
What is happening?
14
ADVERTISING PRE-APPROVALS – BACKGROUND
• Some advertisements for Therapeutic goods need to be approved before use:
• Medicines only
• Certain media only (broadcast and print)
• Up until Nov 2019 separate industry associations had the delegated responsibilities
• now CHP Australia does them all
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
WHAT IS HAPPENING?
• After decades protecting consumers and advertisers, the mandatory pre-approvals
of therapeutic goods advertising to consumers is coming to an end.
• From 1 July 2020, it will no longer be mandatory to have any therapeutic goods
advertising to consumers approved before publication.
• Obligations remain, for advertisers and those who “cause” advertising for ALL forms
of media
• CHP Australia will be offering a voluntary Advertising Advisory Service called
AdCheck which we will launch on 1 July 2020
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
Why is the Government abolishing mandatory pre-approvals?
17
REGULATORY REFORM-MMDR
MMDR (Medicines and Medical Devices Review)- July 2015
Recommendation #55 to gov’t:
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
The Panel recommends that the whole process of vetting and pre-
approval of the advertising of therapeutic products to the public is
stopped in favour of a more self-regulatory regime.
REGULATORY REFORM-MMDR
Government response to MMDR Recommendation #55 – May 2016
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
Accepted … noting that the acceptance of Recommendations Fifty-Seven
(enforcement powers) and Fifty-Eight (sponsor education) is critical
for managing potential concerns by consumers and healthcare
professionals in accepting this recommendation.
REGULATORY REFORM-MMDR
Senate’s Community Affairs Legislation Committee- Feb 2018
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
The committee notes the importance of self-regulatory models and
recommends that the Therapeutic Goods Administration investigate ways to
better support the effective functioning of self-regulatory models by
industry, including the potential for further strengthening of the
penalties regime if needed.
What else has changed?
21
THIS CHANGE IS NOT HAPPENING IN ISOLATION
In the lead up to 1 July 2020, and in consequence of the MMDR
reforms, there have been significant changes to the whole suite of
therapeutic goods regulation, but especially the following related
changes:
• New TGAC (Therapeutic Goods Advertising Code)
• New Advertising complaints processes
• Increased Sanctions and penalties
22 SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
NEW TGAC
(THERAPEUTIC GOODS ADVERTISING CODE)
• No substantive change in the TGAC between 2005 and 2018
• Three recent versions of the Code
• (June 2018, October 2018 and July 2019)
• More changes coming?
• Members and other stakeholders tell us that the new Code:
• Still some uncertainty as to precise requirements
• Still has subjective elements
• Also has problematic elements
• Needs to be read together with TGA Guidelines, Advertising Hub, Etc
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
23
NEW COMPLAINTS PROCESS
• New decision maker
• New approach to publication of determinations
• Members and other stakeholders tell us that:
• The new process makes it difficult to ascertain exactly what is happening.
• It is difficult to see how the TGA are approaching the more subtle,
nuanced, subjective elements of the TGAC
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
24
INCREASED SANCTIONS & PENALTIES
Increase in TGA’s penalties and sanctions
(per the Explanatory Memorandum):
• “stronger compliance and enforcement powers”
• “broader sanctions and penalties”
• “to protect the public”
• “to allow the TGA to respond appropriately”
• Broadening the TGA’s investigation and enforcement powers “is
critical for managing potential concerns by consumers and
healthcare professionals in accepting recommendation #55” (the
removal of pre-approvals)
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE25
RANGE OF SANCTIONS & PENALTIES
The TGA has a wide range of enforcement tools:
• Educational letters and educational visits
• Referrals
• Warning letters
• Substantiation notices
• Directions
• Public warning notices
• Infringement notices
• Enforceable undertakings
• Criminal prosecution
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE26
SERIOUSNESS OF SANCTIONS & PENALTIES
The TGA’s enforcement tools range in seriousness depending on:
• the nature of the breach,
• the advertiser's attitude towards compliance,
• history of non-compliance and
• potential risk to the public
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE27
And all those who advertise or who ‘cause the advertising’
are liable
RANGE OF PENALTIES
Criminal penalties:
• Up to 5 years' imprisonment and up to $840,000 for individuals
• Up to $8.4 million for companies
Civil penalties:
• Up to $1.0 million for individuals
• Up to $10 million for companies
Breach of the TGAC (criminal penalties):
• Up to 5 years' imprisonment and up to $840,000 for individuals
Breach of the TGAC (civil penalties)
• Up to $1.0 million for individuals
• Up to $10 million for companies
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
RECENT ENFORCEMENT EXAMPLES
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
2020 2019
ATP Science issued infringement notices for
$302,400
Mundipharma fined $302,400
Oxymed Australia Pty Ltd fined $63,000 PharmaCare pays $12,600 fine
Court proceedings commenced against
Evolution Supplements Australia and its sole
director (interim injunction granted 3 April)
$10 million penalty ordered against Peptide
Clinics Pty Ltd
Caruso’s Natural Health fined $12,600 Individual fined for alleged importation and
advertising of unapproved therapeutic goods
Multi-level marketing company fined $37,800
InSkin Cosmedics Group pays $37,800
What will take the place of mandatory pre-approvals?
30
SELF REGULATION
As per MMDR, gov’t response and Senate Committee
recommendations, a self regulatory system will replace mandatory
pre-approvals
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
CHP Australia will establish an Advertising Advisory Service
From 1 July 2020
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
How will the new service work?
33
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
Voluntary, self-regulatory
advertising compliance
service:
•All advertisers
•All media
•Medicines and devices
Anticipated benefits for:
•Consumers
•Advertisers
•Those who “cause the advertising”
•The TGA
Expert knowledge of TGA Code
•Current CHP Australia ASMs for pre
approvals will be performing AdChecks
•Will provide advice, not just a ‘yes/no’
on compliance
Pricing and Processes
•similar to current pre
approvals
•new efficiencies built-in
HOW WORKS
• Online submission via CHP Australia website
• Immediate acknowledgement and generation of invoice
• Assessor provides prompt feedback
• Provision of advice where necessary to achieve compliance
• If considered compliant
• a unique AdCheck number will be issued
• the number can be included in the advertisement
• the number can be verified by other parties via an online request through our website
• If considered non-compliant
• advice will be provided on achieving compliance
• if not capable of being made compliant, we will close the application
• there will be no “rejected” advertisements
•SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
https://youtu.be/EBMRhmjxH-8
VIDEO (ALTERNATE- VIA YOUTUBE)
What does it mean to “advertise”?
What does it mean to “cause” advertising?
38
COMPLIANCE
• Advertising offences in the Act apply to parties who “advertise”
and parties who “cause the advertising”
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
TO ADVERTISE…
The Therapeutic Goods Act (section 3) provides this (very broad)
definition:
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
Advertise, in relation to therapeutic goods, includes make any
statement, pictorial representation or design that is intended, whether
directly or indirectly, to promote the use or supply of the goods….
TO “CAUSE” ADVERTISING…
• Not defined, but the TGA provides the following (non-exhaustive) list of parties who might be said to have “caused” the advertising:
• sponsors
• manufacturers, wholesalers, retailers, franchisees, multi-level marketers
• publishers, broadcasters, datacasters,
• internet or mobile service providers, or any other media service providers
• advertising agencies
• influencers, bloggers and product ambassadors
• any person publicly endorsing the goods
• print or broadcast organisations
• health practitioners
•
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON SCHOOMBIE
ANY EXCEPTIONS?
• Under the Act, advertisers and those who “cause” advertising are
responsible for compliance, but there are some limited
exceptions:
• Section 42DLB (Civil penalty relating to advertisements—
general)
• Section 42DMA, (Civil penalty—non-compliance with the
Therapeutic Goods Advertising Code)
• More about this below
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
Publisher exceptions?
43
PUBLISHER EXCEPTIONS
• Sections 42DLB and 42DMA, provide some protection for “broadcasters, datacasters and the SBS”
• Regulation 7A extends this protection to any person who is “a publisher of a print edition of a newspaper or magazine that is or was available to the public by way of purchase in Australia.”
BUT, only where:
• “as a result of steps taken by the person, it was reasonable for the person to assume that” the advertising was compliant etc.
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
WHAT DOES THIS MEAN?
• Only these specified parties can take advantage of the protection
• Only these specific sections of the Act are covered by the protection, AND
• In order to take advantage of the defence, the person has to show that it was reasonable to assume that the advertising was compliant because of relevant steps they took to ensure compliance.
• Relatively easy to do that now when the advertising is approved, but…
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
• Taking the word of the advertiser?
• Assessing the compliance themselves (with in-house expertise)?
• Relying on a credible third-party compliance service?
• Others?
Without mandatory pre-approvals, what are the options open to these persons?
Why does CHP Australia support preapprovals (now) and compliance reviews (in the future)?
46
CURRENT SITUATION WITH PRE APPROVALS
• An estimated 60-70% of advertisements submitted to the CHP ASMs for pre-approval require some form of amendment.
• Ranging from relatively small amendments to major reviews of advertisements.
• Without pre-approval consumers would have been exposed to those non-compliant advertisements and sponsors would have been subject to penalties or sanctions.
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
CURRENT SITUATION WITH PRE APPROVALS
• Only 5% to 9% of the complaints found justified by the
Complaints Resolution Panel involved advertising that
had been pre-approved.
• The remainder are advertisements which were not subject
to mandatory pre-approval (e.g. social media, websites, etc)
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
Why would you want to use the new AdCheck service?
49
BENEFITS – ADVERTISERS
• Arm’s-length, objective, review of materials
• Reducing the likelihood of breaches occurring
• CHP Australia will offer assistance if a complaint is received
• We think the fact that an advertiser used the AdCheck service should be taken into account as a mitigating factor should a breach subsequently be found (i.e. an advertiser’s “attitude towards compliance” and past behaviour is relevant in determining the appropriate penalty/sanction if any).
Also:
• Demonstration of good faith and respect for the relationship with those who “cause” the advertising
• Reassurance for those who “cause” advertising
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
BENEFITS – THOSE WHO “CAUSE” ADVERTISING
• The publisher exceptions offer some protection (where “steps taken by the person” make it “reasonable … to
assume that” the advertising was compliant)
• What steps can you take?
• Become an expert yourself?
• Trust the advertiser completely?
• Rely on a third-party compliance review?
• Other steps?
• If you do not meet the requirements for a publisher exception, should the fact that the AdCheck
service was used be taken into account as a mitigating factor? Yes.
• If you do meet the requirements for a publisher exception, can a third-party compliance review (like
AdCheck) allow you to reasonably assume that the advertising is compliant? We think so.
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
BENEFITS
Consumers
• Protection from exposure to non-compliant advertising
TGA
• Reduction in the number of non-compliant advertising?
• Reduction in the number of complaints?
• Able to focus attention on advertising not subject to review?
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
BENEFITS
Industry
In addition to the benefits for individual advertisers, this will be a
demonstration to all stakeholders that we are a mature, responsible
industry, something we will all benefit from.
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
Summary
54
KEY POINTS
• Mandatory pre-approvals are being abolished “in favour of a
more self-regulatory regime”
• At the same time a number of changes are also being made
• And penalties and sanctions have been increased
• Advertisers and those who “cause” advertising are responsible
for compliance
• CHP Australia is providing AdCheck, a voluntary compliance
service from 1 July 2020 which we anticipate will be of benefit to
all stakeholders
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM TO DEON
SCHOOMBIE
QUESTIONS?
SEND QUESTIONS VIA Q&A FUNCTION on ZOOM
TO DEON SCHOOMBIE